«Previous Article|Table of Contents|Next Article»

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:

2023 17

Page:

3325-3330

Research Field:

Publishing date:

Info

Title:

Advance in targeted therapy of KRAS-mutant non-small cell lung cancer

Author(s):

HOU Xuenan¹; 2; GUO Zehuai¹; 2; CAO Yang²

1.The First Clinical School of Guangzhou University of Chinese Medicine£¬Guangdong Guangzhou 510405£¬China£»2.Department of Medical Oncology£¬the First Affiliated Hospital of Guangzhou University of Chinese Medicine£¬Guangdong Guangzhou 510405£¬China.

Keywords:

non-small cell lung cancer; KRAS mutation; targeted therapy; immunotherapy

PACS:

R734.2

DOI:

10.3969/j.issn.1672-4992.2023.17.034

Abstract:

Lung cancer is the malignancy with the highest incidence,and KRAS is one of the main mutated genes in non-small cell lung cancer.The treatment of KRAS has problems such as poor efficacy,weak specificity and insufficient safety,which makes KRAS mutant non-small cell lung cancer a research hotspot.This article reviews the mechanism and efficacy of targeted therapy in KRAS mutant non-small cell lung cancer,in order to provide directions and goals for the future research.

References:

£Û1£ÝÖ£ÈÙÊÙ£¬Ëï¿ÉÐÀ£¬ÕÅ˼ά£¬µÈ.2015ÄêÖйú¶ñÐÔÖ×ÁöÁ÷ÐÐÇé¿ö·ÖÎö£ÛJ£Ý.ÖлªÖ×ÁöÔÓÖ¾£¬2019£¬41(01):19-28. ZHENG RS,SUN KX,ZHANG SW,et al.Analysis of cancer prevalence in China in 2015 £ÛJ£Ý.Chinese Journal of Oncology,2019,41(01):19-28.
£Û2£Ý RE MD,ROFI E,RESTANTE G,et al.Implications of KRAS mutations in acquired resistance to treatment in NSCLC £ÛJ£Ý.Oncotarget,2018,9(5):6630-6643.
£Û3£Ý GOULDING RE,CHENOWETH M,CARTER GC,et al.KRAS mutation as a prognostic factor and predictive factor in advanced/metastatic non-small cell lung cancer:A systematic literature review and meta-analysis £ÛJ£Ý.Cancer Treat Res Commun,2020,24:100200.
£Û4£Ý ROM¦BN M,BARAIBAR I,L¦VPEZ I,et al.KRAS oncogene in non-small cell lung cancer:clinical perspectives on the treatment of an old target £ÛJ£Ý.Mol Cancer,2018,17(1):33.
£Û5£Ý TOMASINI P,WALIA P,LABBE C,et al.Targeting the KRAS pathway in non-small cell lung cancer £ÛJ£Ý.Oncologist,2016,21(12):1450-1460.
£Û6£Ý HERDEIS L,GERLACH D,MCCONNELL DB,et al.Stopping the beating heart of cancer:KRAS reviewed £ÛJ£Ý.Curr Opin Struct Biol,2021,71:136-147.
£Û7£Ý DEARDEN S,STEVENS J,WU YL,et al.Mutation incidence and coincidence in non small-cell lung cancer:meta-analyses by ethnicity and histology(mutMap) £ÛJ£Ý.Ann Oncol,2013,24(9):2371-2376.
£Û8£ÝRUPPERT AM,BEAU-FALLER M,DEBIEUVRE D,et al.Outcomes of patients with advanced NSCLC from the intergroupe francophone de canc¨¦rologie thoracique biomarkers france study by KRAS mutation subtypes £ÛJ£Ý.JTO Clin Res Rep,2020,1(3):100052.
£Û9£Ý IHLE NT,BYERS LA,KIM ES,et al.Effect of KRAS oncogene substitutions on protein behavior:implications for signaling and clinical outcome £ÛJ£Ý.J Natl Cancer Inst,2012,104(3):228-239.
£Û10£Ý MELLEMA WW,DINGEMANS AM,THUNNISSEN E,et al.KRAS mutations in advancednonsquamous non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy have no predictive value £ÛJ£Ý.J Thorac Oncol,2013,8(9):1190-1195.
£Û11£Ý GOULDING RE,CHENOWETH M,CARTER GC,et al.KRAS mutation as a prognostic factor and predictive factor in advanced/metastatic non-small cell lung cancer:A systematic literature review and meta-analysis £ÛJ£Ý.Cancer Treat Res Commun,2020,24:100200.
£Û12£ÝNADAL E,CHEN G,PRENSNER JR,et al.KRAS-G12C mutation is associated with poor outcome in surgically resected lung adenocarcinoma £ÛJ£Ý.J Thorac Oncol,2014,9(10):1513-1522.
£Û13£ÝWALLER DD,PARK J,TSANTRIZOS YS.Inhibition of farnesyl pyrophosphate(FPP) and/or geranylgeranyl pyrophosphate(GGPP) biosynthesis and its implication in the treatment of cancers £ÛJ£Ý.Crit Rev Biochem Mol Biol,2019,54(1):41-60.
£Û14£ÝODENIYIDE P,YOHE ME,POLLARD K,et al.Targeting farnesylation as a novel therapeutic approach in HRAS-mutant rhabdomyosarcoma £ÛJ£Ý.Oncogene,2022,41(21):2973-2983.
£Û15£Ý DHILLON S.Lonafarnib:first approval published correction appears in drugs £ÛJ£Ý.Drugs,2021,81(2):283-289.
£Û16£ÝLEE KH,KOH M,MOON A. Farnesyl transferase inhibitor FTI-277 inhibits breast cell invasion and migration by blocking H-Ras activation £ÛJ£Ý.Oncol Lett,2016,12(3):2222-2226.
£Û17£ÝMARCHWICKA A,KAMINSKA D,MONIRIALAMDARI M,et al.Protein prenyltransferases and their inhibitors:structural and functional characterization £ÛJ£Ý.Int J Mol Sci,2022,23(10):5424.
£Û18£ÝMOORE AR,ROSENBERG SC,MCCORMICK F,et al.RAS-targeted therapies:is the undruggable drugged£ÛJ£Ý.Nat Rev Drug Discov,2020,19(8):533-552.
£Û19£Ý LITO P,SOLOMON M,LI LS,et al.Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism £ÛJ£Ý.Science,2016,351(6273):604-608.
£Û20£Ý PATRICELLI MP,JANES MR,LI LS,et al.Selective inhibition of oncogenic KRAS output with small molecules targeting the inactive state £ÛJ£Ý.Cancer Discov,2016,6(3):316-329.
£Û21£ÝFDA approves first targeted therapy for lung cancer mutation previously considered resistant to drug therapy£ÛR£Ý.US Food and Drug Administration,2021.
£Û22£Ý SKOULIDIS F,LI BT,DY GK,et al.Sotorasib for lung cancers with KRAS p.G12C mutation £ÛJ£Ý.N Engl J Med,2021,384(25):2371-2381.
£Û23£Ý DE LANGEN AJ,JOHNSON ML,MAZIERES J,et al.Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation:a randomised,open-label,phase 3 trial £ÛJ£Ý.Lancet,2023,401(10378):733-746.
£Û24£Ý U.S.Food and Drug Administration(FDA) accepts Mirati Therapeutics' new drug application for adagrasib as treatment of previously treated KRAS G12C-mutated non-small cell lung cancer £ÛN£Ý.Mirati Therapeutics,2022.
£Û25£Ý ¦FNNE PA,RIELY GJ,GADGEEL SM,et al.Adagrasib in non-small-cell lung cancer harboring a KRASG12C mutation £ÛJ£Ý.N Engl J Med,2022,387(2):120-131.
£Û26£ÝWANG X,ALLEN S,BLAKE JF,et al.Identification of MRTX1133,a noncovalent,potent,and selective KRAS(G12D) inhibitor £ÛJ£Ý.J Med Chem,2022,65:3123-3133.
£Û27£ÝHOFMANN MH,GMACHL M,RAMHARTER J,et al.BI-3406,a potent and selective SOS1-KRAS interaction inhibitor,is effective in KRAS-driven cancers through combined MEK inhibition£ÛJ£Ý.Cancer Discov,2021,11(1):142-157.
£Û28£Ý ZHOU C,FAN Z,ZHOU Z,et al.Discovery of the first-in-class agonist-based SOS1 PROTACs effective in human cancer cells harboring various KRAS mutations £ÛJ£Ý.J Med Chem,2022,65(5):3923-3942.
£Û29£Ý MULLARD A.Cracking KRAS £ÛJ£Ý.Nat Rev Drug Discov,2019,18(12):887-891.
£Û30£ÝBUSAIDY NL,KONDA B,WEI L,et al.Dabrafenib versus dabrafenib+trametinib in braf-mutated radioactive iodine refractory differentiated thyroid cancer:results of a randomized,phase 2,open-label multicenter trial £ÛJ£Ý.Thyroid,2022,32(10):1184-1192.
£Û31£ÝMAZIERES J,CROPET C,MONTAN¦I L,et al.Vemurafenib in non-small-cell lung cancer patients with BRAFV600 and BRAFnonV600 mutations £ÛJ£Ý.Ann Oncol,2020,31(2):289-294.
£Û32£Ý DEGIRMENCI U,WANG M,HU J.Targeting aberrant RAS/RAF/MEK/ERK signaling for cancer therapy £ÛJ£Ý.Cells,2020,9(1):198.
£Û33£Ý TAKEZAWA K,OKAMOTO I,YONESAKA K,et al.Sorafenib inhibits non-small cell lung cancer cell growth by targeting B-RAF in KRAS wild-type cells and C-RAF in KRAS mutant cells £ÛJ£Ý.Cancer Res,2009,69(16):6515-6521.
£Û34£Ý DINGEMANS AM,MELLEMA WW,GROEN HJ,et al.A phase II study of sorafenib in patients with platinum-pretreated,advanced(Stage IIIb or IV) non-small cell lung cancer with a KRAS mutation £ÛJ£Ý.Clin Cancer Res,2013,19(3):743-751.
£Û35£Ý PAZ-ARES L,HIRSH V,ZHANG L,et al.Monotherapy administration of sorafenib in patients with non-small cell lung cancer(MISSION) trial:a phase ¢ó,multicenter,placebo-controlled trial of sorafenib in patients with relapsed or refractory predominantly nonsquamous non-small-cell lung cancer after 2 or 3 previous treatment regimens£ÛJ£Ý.J Thorac Oncol,2015,10(12):1745-1753.
£Û36£ÝKIM ES,HERBST RS,WISTUBA II,et al.The BATTLE trial:personalizing therapy for lung cancer £ÛJ£Ý.Cancer Discov,2011,1(1):44-53.
£Û37£Ý DAVIES BR,LOGIE A,MCKAY JS,et al.AZD6244(ARRY-142886),a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases:mechanism of action in vivo,pharmacokinetic/pharmacodynamic relationship,and potential for combination in preclinical models £ÛJ£Ý.Mol Cancer Ther,2007,6(8):2209-2219.
£Û38£Ý J¦FNNE PA,SMITH I,MCWALTER G,et al.Impact of KRAS codon subtypes from a randomised phase ¢ò trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer £ÛJ£Ý.Br J Cancer,2015,113(2):199-203.
£Û39£Ý J¦FNNE PA,VAN DEN HEUVEL MM,BARLESI F,et al.Selumetinib plus docetaxel compared with docetaxel alone and progression-free survival in patients with KRAS-mutant advanced non-small cell lung cancer:the SELECT-1 randomized clinical trial£ÛJ£Ý.JAMA,2017,317(18):1844-1853.
£Û40£Ý ARBOUR KC,MANCHADO E,BOTT MJ,et al.Phase 1 clinical trial of trametinib and ponatinib in patients with NSCLC harboring KRAS mutations £ÛJ£Ý.JTO Clin Res Rep,2021,3(1):100256.
£Û41£Ý FROESCH P,MARK M,ROTHSCHILD SI,et al.Binimetinib,pemetrexed and cisplatin,followed by maintenance of binimetinib and pemetrexed in patients with advanced non-small cell lung cancer(NSCLC) and KRAS mutations.The phase 1B SAKK 19/16 trial £ÛJ£Ý.Lung Cancer,2021,156:91-99.
£Û42£Ý GUO C,CH¦INARD-POIRIER M,RODA D,et al.Intermittent schedules of the oral RAF-MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma:a single-centre,open-label,phase 1 dose-escalation and basket dose-expansion study £ÛJ£Ý.Lancet Oncol,2020,21(11):1478-1488.
£Û43£Ý CAPELLETTO E,BIRONZO P,DENIS L,et al.Single agent VS-6766 or VS-6766 plus defactinib in KRAS-mutant non-small-cell lung cancer:the RAMP-202 phase II trial £ÛJ£Ý.Future Oncol£¬2022,18(16):1907-1915.
£Û44£Ý CHAN CH,CHIOU LW,LEE TY,et al.PAK and PI3K pathway activation confers resistance to KRASG12C inhibitor sotorasib £ÛJ£Ý.Br J Cancer,2023,128(1):148-159.
£Û45£Ý ENGELMAN JA,CHEN L,TAN X,et al.Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers £ÛJ£Ý.Nat Med,2008,14(12):1351-1356.
£Û46£Ý SHIMIZU T,TOLCHER AW,PAPADOPOULOS KP,et al.The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer £ÛJ£Ý.Clin Cancer Res,2012,18(8):2316-2325.
£Û47£Ý MISALE S,FATHERREE JP,CORTEZ E,et al.KRAS G12C nsclc models are sensitive to direct targeting of KRAS in combination with PI3K inhibition £ÛJ£Ý.Clin Cancer Res,2019,25(2):796-807.
£Û48£Ý YANG Z,LIANG SQ,ZHAO L,et al.Metabolic synthetic lethality by targeting NOP56 and mTOR in KRAS-mutant lung cancer £ÛJ£Ý.J Exp Clin Cancer Res,2022,41(1):25.
£Û49£Ý RIELY,GREGORY J.A randomized discontinuation phase ¢ò trial of ridaforolimus in non-small cell lung cancer(NSCLC) patients with KRAS mutations £ÛJ£Ý.J Clin Oncol,2012,30:7531-7531.
£Û50£Ý BOGUCKA K,MARINI F,ROSIGKEIT S,et al.ERK3/MAPK6 is required for KRAS-mediated NSCLC tumorigenesis £ÛJ£Ý.Cancer Gene Ther,2021,28(5):359-374.
£Û51£Ý KONSTANTINIDOU G,RAMADORI G,TORTI F,et al.RHOA-FAK is a required signaling axis for the maintenance of KRAS-driven lung adenocarcinomas £ÛJ£Ý.Cancer Discov,2013,3(4):444-457.
£Û52£ÝZHANG B,ZHANGY,ZHANG,et al.Focal adhesion kinase£¨FAK£©inhibition synergizes with KRAS G12C inhibitors in treating cancer through the regulation of the FAK-YAP signaling £ÛJ£Ý.Adv Sci(Weinh),2021,8(16):e2100250.
£Û53£Ý GERBER DE,CAMIDGE DR,MORGENSZTERN D,et al.Phase 2 study of the focal adhesion kinase inhibitor defactinib(VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer £ÛJ£Ý.Lung Cancer,2020,139:60-67.

Memo

Memo:

National Natural Science Foundation of China(No.82174456£©£»¹ú¼Ò×ÔÈ»¿Æѧ»ù½ðÃæÉÏÏîÄ¿£¨±àºÅ£º82174456);¹ãÖÝÖÐÒ½Ò©´óѧµÚÒ»¸½ÊôÒ½Ôº´´ÐÂÇ¿Ôº¶þÆÚ¹¤³Ì£¨±àºÅ£º2019IIT27£©

Common functions

Last Update: 2023-07-31